| 2026-08-04 | Press release | Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 |
| 2026-08-04 | Press release | July 21, 2026 Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 |
| 2026-07-30 | Financial supplement | Q2 2026 Supplementary Information |
| 2026-05-07 | Presentation | Resource Book |
| 2026-05-07 | Press release | Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 |
| 2026-04-07 | Press release | Gilead Sciences Update: Proposed Tubulis, Ouro, and Arcellx Acquisitions |
| 2026-02-10 | Press release | Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 |
| Press release | June 24, 2026 U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer |
| Press release | June 15, 2026 U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First |
| Press release | July 21, 2026 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virologica |
| Press release | July 21, 2026 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure |
| Press release | June 23, 2026 European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Can |
| Press release | July 24, 2026 CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negativ |
| Press release | Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results |
| Press release | Gilead Sciences Announces Second Quarter 2021 Financial Results |
| Press release | Gilead Sciences Announces First Quarter 2021 Financial Results |
| Press release | Gilead Sciences Announces Third Quarter 2021 Financial Results |
| Press release | U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenaca |
| Press release | U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer |
| Press release | U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pi |
| Press release | PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Acces |
| Press release | New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a |
| Press release | New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in On |
| Press release | National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Lead |
| Press release | Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study |
| Press release | Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression |
| Press release | Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure |
| Press release | Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 |
| Press release | Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Furth |
| Press release | Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who |
| Press release | Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in |
| Press release | Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences |
| Press release | Gilead Sciences to Present at Upcoming Investor Conferences |
| Press release | Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases |
| Press release | Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel |
| Press release | Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio |
| Press release | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel |
| Press release | Gilead Sciences Announces Second Quarter 2026 Financial Results |
| Press release | Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results |
| Press release | Gilead Sciences Announces First Quarter Financial Results |